Dr. Locke on the ZUMA-1 Trial of KTE-C19 for Lymphoma


Fred Locke, MD, Moffitt Cancer Center discusses the interim results of the ZUMA-I trial of Kte-C19, a CAR T-cell therapy.

Frederick Locke, MD, Moffitt Cancer Center, discusses the interim results of the phase II pivotal ZUMA-1 trial of the anti-CD19 CAR T-cell therapy KTE-C19 for patients with refractory aggressive non-Hodgkin's lymphoma.

The ZUMA-1 study looked at KTE-C19 for patients with lymphoma that was chemotherapy-refractory or following relapse within 12 months of an autologous transplant. These patients were heavily pretreated with a median of 3 prior treatments but could have received as many as 12 treatment. Of the 111 patients enrolled 101 received therapy. At the time of this interim report, there were 93 patients who had at least 1 month of follow-up. There were 62 patients with ≥3 months of follow-up.

Of the 93 patients, there was a 53% overall response rate (ORR) and a 38% complete response (CR) rate. In those with ≥3 months follow-up, the ORR was 79% and the CR rate was 52%. In those relapsing post transplant (n = 12), the CR was 75%. In those refractory to ≥2 therapies (n = 49), the CR rate was 47%.


View more from the 2017 BMT Tandem Meetings

Related Videos
Judy Lieberman, MD, PhD, the endowed chair in cellular and molecular medicine at Boston Children’s Hospital
Alexandra Gomez Arteaga, MD
Paul Harmatz, MD
Mark Walters, MD
Mitchel Horwitz, MD
Bruce Cree, MD, PhD, MAS, a professor of neurology and the clinical research director of the University of California San Francisco (UCSF) Multiple Sclerosis Center
Emilie Aschenbrenner, PharmD, BCOP, a hematology coordinator for pharmacy at Froedtert and the Medical College of Wisconsin
Raj Chovatiya, MD, PhD
Jessica S. Little, MD, a transplant infectious diseases physician at Dana-Farber Cancer Institute
© 2024 MJH Life Sciences

All rights reserved.